Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
October 27, 2020
Assignee:
Jubilant Generics Limited
Inventors:
Pankaj Soni, Rashmi Ranjan Panda, Ganesh Vinayak Gat, Dinesh Kumar, Kamal S. Mehta, Ravikumar Nithiyanandam
Abstract: An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device.
Abstract: A pharmaceutical composition of high drug loading comprising an active pharmaceutical ingredient (API) and pharmaceutical acceptable additives, which include glass-solution forming additive and/or eutectic-mixture forming additive, is provided. The composition is dispersed uniformly to form a hybrid solid dispersion consisting of crystalline-suspension, glass-solution and/or eutectic-mixture, where the crystalline API is uniformly distributed in the hybrid solid dispersion and exists in nano/micro particle size range. The amorphous API, when present, is uniformly distributed in the hybrid solid dispersion. The API may exist in different chemical and/or physical forms. The API is present in an amount of from more than about 50% wt/wt to about 90% wt/wt with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives.
Abstract: Procedure for preparing enteric-coated pellets containing a proton pump inhibitor with benzimidazole structure, useful for preparing multi-particle pharmaceutical compositions for oral use that comprises the following stages: I) coat pure cellulose cores with a hydroalcoholic suspension that contains the proton pump inhibitor, a dibasic amino acid and polyvinylpyrrolidone; II) isolate the coated pure cellulose cores obtained in Stage I; III) apply an enteric coating to the particles obtained in Stage II above; and IV) dry the particles obtained in Stage III above and separate by size.
Type:
Grant
Filed:
March 31, 2015
Date of Patent:
September 29, 2020
Assignees:
Laboratorios Bago S.A., Eastbrand Holding GMBH
Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.
Type:
Grant
Filed:
April 10, 2018
Date of Patent:
September 29, 2020
Assignee:
THERAVIDA, INC.
Inventors:
Mehdi Paborji, Robert V. Tuohy, III, Peter R. P. Freed, Roger S. Flugel
Abstract: A wet wipe includes a cleansing composition and a substrate. The cleansing composition includes a preservative enhancing agent selected from the group consisting of caprylyl glycol; caprylyl glyceryl ether; glyceryl caprylate; sorbitan caprylate; ethylhyexyl glycerin, and combinations thereof. The cleansing composition includes a preservative selected from the group consisting of benzoic acid; lactic acid; sorbic acid; malic acid; maleic acid, and combinations thereof. The cleansing composition has a pH less than about 4. A method of making the cleansing composition may include dissolving one or more preservatives with water to form a solution; adding a rheology modifier to the solution; adding an emulsifier to the solution; adding a preservative enhancing agent to the solution; and adding citric acid to the solution.
Type:
Grant
Filed:
December 18, 2019
Date of Patent:
September 22, 2020
Assignee:
The Procter & Gamble Company
Inventors:
Charles Allen Pettigrew, Justin Angelo Caserta, Donna Jane Wiedemann
Abstract: A composition for topical application, in the form of an oil-in-water emulsion, containing at least one nonionic emulsifier with a melting point of less than 45° C. and at least one 2-acrylamido-2-methylpropanesulfonic acid polymer. The composition shows very good stability.
Abstract: Esterified cellulose ethers which have i) as ester groups aliphatic monovalent acyl groups or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, ii) a weight average molecular weight Mw of from 80,000 Dalton to 220,000 Dalton, iii) a Polydispersity Mw/Mn of from 1.3 to 4.0, and iv) an Mz/Mn of not more than 18.5, when the weight average molecular weight Mw, the number average molecular weight Mn and the z-average molecular weight Mz are measured by SEC-MALLS using as mobile phase a mixture produced from 40 parts by volume of acetonitrile and 60 parts by volume of aqueous buffer containing 50 mM NaH2—PO4 and 0.1 M NaNO3. are useful as enteric polymers for pharmaceutical dosage forms.
Type:
Grant
Filed:
January 27, 2015
Date of Patent:
September 1, 2020
Assignee:
Dow Global Technologies LLC
Inventors:
Oliver Petermann, Matthias Sprehe, Meinolf Brackhagen
Abstract: Nanoparticle based MKT formulation. MKT is encapsulated by poly(ethylene glycol)ylated (PEGylated) poly-(lactide-co-glycolide) (PLGA) to form nanoparticles (NPs). To induce trans-BBB permeability, glutathione (GSH) is coated on the resulting NPs. Newly generated MKT-NPs showed BBB permeability and tau reduction in experimental models. Specifically, brain-targeting MKT NPs were developed with a glutathione coating, characterized, and shown to permeate BBB permeation insert models as a therapeutic for Alzheimer's disease and related tauopathies.
Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
September 1, 2020
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
Abstract: Pharmaceutical blends are disclosed herein. In some embodiments, a pharmaceutical blend includes a cohesive active pharmaceutical ingredient (API) and a dry coated pharmaceutical excipient. The dry coated pharmaceutical excipient is present in an amount of about 1 wt % to 99 wt %, based on the total weight of the pharmaceutical blend. The dry coated pharmaceutical excipient includes a core and a shell surrounding the core, wherein the shell partially covers the core of the pharmaceutical excipient.
Abstract: There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
August 11, 2020
Assignee:
W.L Gore & Associates, Inc.
Inventors:
Karin Leontein, Per Antoni, Daniel Nyström, Paul Begovac, Krzysztof Pietrzak
Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
August 4, 2020
Assignee:
Humanetics Corporation
Inventors:
Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
Abstract: The present disclosure provides a pharmaceutical preparation of a compound of formula (I) or a stereoisomer, pharmaceutically acceptable salt, or prodrug thereof. The present disclosure further provides a method for general anesthesia or sedation for mammals. Also provided are kits and manufactured products of the medicament and the pharmaceutical composition and a method for using the medicament and the pharmaceutical composition.
Abstract: A liquid foamable composition includes a cationic surfactant, a nonionic surfactant, or mixtures of these surfactants, a fatty alcohol, a silicone blend, and water. The silicone blend includes a silicone gel and a silicone powder. A foam composition, an aerosol product, and methods for improving sensory benefits to skin are also provided.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
July 21, 2020
Assignee:
The Procter & Gamble Company
Inventors:
Jorge Max Sunkel, Dean Arthur Zimmerman
Abstract: Lipid nanocapsules are described that include at least one irritating active ingredient, and more specifically a retinoid in solubilized form. Also described, are nanodispersions and pharmaceutical compositions including the same and methods of producing the same. The use of the pharmaceutical compositions in the treatment of dermatological pathologies is also described.
Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
June 2, 2020
Assignee:
Collegium Pharmaceutical, Inc.
Inventors:
Roman V. Rariy, Alison Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
Abstract: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”).
Abstract: Provided herein relates to compositions and methods for lubrication of a surface. The surface amenable to the compositions and methods described herein can be a non-biological surface, a biological surface, or a combination thereof. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for lubrication of a surface. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for joint lubrication, e.g., for treatment of joint disorders such as arthritis.
Type:
Grant
Filed:
April 25, 2013
Date of Patent:
May 19, 2020
Assignees:
TRUSTEES OF TUFTS COLLEGE, Tulane Educational Fund
Inventors:
David L. Kaplan, Xiaoqin Wang, Vijay John, Noshir Pesika, Rubo Zheng